PCSK9 inhibition for acute arterial events: more than LDL lowering-Reference-Cited by-同舟云学术

PCSK9 inhibition for acute arterial events: more than LDL lowering

Published:2021-10-25 Issue:47 Volume:42 Page:4830-4832
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Orringer Carl E¹^ORCID

Affiliation:

1. Department of Internal Medicine, Division of Cardiovascular Disease, University of Miami Miller School of Medicine, Miami, FL, USA

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/42/47/4830/41742183/ehab739.pdf

Reference14 articles.

1. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017

2. Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial;Oyama;Eur Heart J,2021

3. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

4. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N Engl J Med,2018

5. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;Circulation,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling;Journal of Advanced Research;2023-09

2. Association between Triglycerides to High-Density Lipoprotein Cholesterol Ratio and Death Risk in Diabetic Patients with New-Onset Acute Coronary Syndrome: A Retrospective Cohort Study in the Han Chinese Population;Reviews in Cardiovascular Medicine;2022-05-26

3. An update on triglyceride-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease;European Heart Journal;2021-12-14